Search research articles
Contact Us
Filters
Showing results (91-100 of 114) with videos related to
Page
of 12
Sort By:
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
ESMO Open
|
May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
M C Garassino, J Khalifa, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Pneumologie (Stuttgart, Germany)
|
November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]
M Lommatzsch, K F Rabe, C Taube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
M Joerger, J von Pawel, S Kraff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 114) with videos related to
Sort By:
Page
of 12
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
ESMO Open
|
May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
M C Garassino, J Khalifa, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Pneumologie (Stuttgart, Germany)
|
November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]
M Lommatzsch, K F Rabe, C Taube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
M Joerger, J von Pawel, S Kraff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 12